| Providence Kodiak Island Med Ltc | |
| 1915 E Rezanof Drive, Kodiak, Alaska 99615 | |
| (907) 486-7800 | |
| Name | Providence Kodiak Island Med Ltc |
|---|---|
| Location | 1915 E Rezanof Drive, Kodiak, Alaska |
| Certified By | Medicare and Medicaid |
| No. of Certified Beds | 22 |
| Occupancy Rate | 98.18% |
| Medicare ID (CCN) | 025030 |
| Legal Business Name | Legal Business Name Not Available |
| Ownership Type | Non Profit - Corporation |
| NPI Number | 1790889400 |
| Organization Name | PROVIDENCE HEALTH & SERVICES WASHINGTON |
| Doing Business As | PROVIDENCE KODIAK ISLAND MEDICAL CENTER |
| Address | 1915 E Rezanof Dr, Kodiak, AK 99615 |
| Phone Number | 907-486-3281 |
News Archive
Although endocrine therapy for breast cancer has shown excellent results in controlling the disease, responsiveness to the therapy depends on whether or not there is expression of estrogen receptors in breast cancer cells. Research from the Sbarro Institute for Cancer Research and Molecular Medicine, a nonprofit cancer, cardiovascular and diabetes research center located in Philadelphia, PA, reports on the effectiveness of a new molecule, Scriptaid, that restores receptivity to endocrine therapy in breast cancer cell lines that had tested negative for the expression of estrogen receptors.
There are potential legal ramifications for physicians of patients who drive with cognitive impairment, according to a study in Clinical Gastroenterology and Hepatology, the official journal of the American Gastroenterological Association Institute.
Most professional athletes are able to return to competition within a year after vertebral fusion surgery on the upper (cervical) spine, reports a study in the July issue of Neurosurgery, official journal of the Congress of Neurological Surgeons. The journal is published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health.
23andMe, Inc., the leading personal genetics company, today announced that it has been granted authority by the U.S. Food and Drug Administration (FDA) to market the first direct-to-consumer genetic test under a regulatory classification for novel devices.
Following the recently announced success achieved during the third round of trials at its research facility at Queen's University (Kingston Ontario, Canada) Medizone International, Inc. announces that a second patent application has been filed which in combination with its previous patent application for AsepticSure™ filed in July of 2009, affords the Company greatly enhanced protection for both the hospital version of AsepticSure™ and the government variant intended for bio-terrorism countermeasures.
› Verified 7 days ago
| NPI Number | 1982708699 |
| Organization Name | PROVIDENCE HEALTH & SERVICES - WASHINGTON |
| Doing Business As | PROVIDENCE KODIAK ISLAND MEDICAL CENTER |
| Address | 1915 E Rezanof Dr, Kodiak, AK 99615 |
| Phone Number | 907-486-3281 |
News Archive
Although endocrine therapy for breast cancer has shown excellent results in controlling the disease, responsiveness to the therapy depends on whether or not there is expression of estrogen receptors in breast cancer cells. Research from the Sbarro Institute for Cancer Research and Molecular Medicine, a nonprofit cancer, cardiovascular and diabetes research center located in Philadelphia, PA, reports on the effectiveness of a new molecule, Scriptaid, that restores receptivity to endocrine therapy in breast cancer cell lines that had tested negative for the expression of estrogen receptors.
There are potential legal ramifications for physicians of patients who drive with cognitive impairment, according to a study in Clinical Gastroenterology and Hepatology, the official journal of the American Gastroenterological Association Institute.
Most professional athletes are able to return to competition within a year after vertebral fusion surgery on the upper (cervical) spine, reports a study in the July issue of Neurosurgery, official journal of the Congress of Neurological Surgeons. The journal is published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health.
23andMe, Inc., the leading personal genetics company, today announced that it has been granted authority by the U.S. Food and Drug Administration (FDA) to market the first direct-to-consumer genetic test under a regulatory classification for novel devices.
Following the recently announced success achieved during the third round of trials at its research facility at Queen's University (Kingston Ontario, Canada) Medizone International, Inc. announces that a second patent application has been filed which in combination with its previous patent application for AsepticSure™ filed in July of 2009, affords the Company greatly enhanced protection for both the hospital version of AsepticSure™ and the government variant intended for bio-terrorism countermeasures.
› Verified 7 days ago
| Ratings from Surveys (Inspections): | |
| Ratings from Quality Measures: | |
| Ratings from Staffing Data: | |
| Overall Rating: |
|---|
News Archive
Although endocrine therapy for breast cancer has shown excellent results in controlling the disease, responsiveness to the therapy depends on whether or not there is expression of estrogen receptors in breast cancer cells. Research from the Sbarro Institute for Cancer Research and Molecular Medicine, a nonprofit cancer, cardiovascular and diabetes research center located in Philadelphia, PA, reports on the effectiveness of a new molecule, Scriptaid, that restores receptivity to endocrine therapy in breast cancer cell lines that had tested negative for the expression of estrogen receptors.
There are potential legal ramifications for physicians of patients who drive with cognitive impairment, according to a study in Clinical Gastroenterology and Hepatology, the official journal of the American Gastroenterological Association Institute.
Most professional athletes are able to return to competition within a year after vertebral fusion surgery on the upper (cervical) spine, reports a study in the July issue of Neurosurgery, official journal of the Congress of Neurological Surgeons. The journal is published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health.
23andMe, Inc., the leading personal genetics company, today announced that it has been granted authority by the U.S. Food and Drug Administration (FDA) to market the first direct-to-consumer genetic test under a regulatory classification for novel devices.
Following the recently announced success achieved during the third round of trials at its research facility at Queen's University (Kingston Ontario, Canada) Medizone International, Inc. announces that a second patent application has been filed which in combination with its previous patent application for AsepticSure™ filed in July of 2009, affords the Company greatly enhanced protection for both the hospital version of AsepticSure™ and the government variant intended for bio-terrorism countermeasures.
› Verified 7 days ago
| Number of Facility Reported Incidents | 0 |
| Number of Substantiated Complaints | 0 |
| Number of Fines | 0 |
| Total Amount of Fines in Dollars | $0 |
| Number of Payment Denials | 0 |
| Total Number of Penalties | 0 |
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Percentage of long-stay residents whose need for help with daily activities has increased | 13.43 | 14.46 |
| Percentage of long-stay residents who lose too much weight | 5 | 5.51 |
| Percentage of low risk long-stay residents who lose control of their bowels or bladder | 50 | 48.41 |
| Percentage of long-stay residents with a catheter inserted and left in their bladder | 4.83 | 1.79 |
| Percentage of long-stay residents with a urinary tract infection | 2.35 | 2.65 |
| Percentage of long-stay residents who have depressive symptoms | 0 | 5.05 |
| Percentage of long-stay residents who were physically restrained | 0 | 0.23 |
| Percentage of long-stay residents experiencing one or more falls with major injury | 1.18 | 3.36 |
| Percentage of long-stay residents assessed and appropriately given the pneumococcal vaccine | 98.82 | 93.87 |
| Percentage of long-stay residents who received an antipsychotic medication | 14.67 | 14.2 |